SWOG S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukaemia

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody ag...

Full description

Saved in:
Bibliographic Details
Main Authors: Advani, Anjali S., McDonough, Shannon, Coutre, Steven, Wood, Brent, Radich, Jerald, Mims, Martha, O’Donnell, Margaret, Elkins, Stephanie, Becker, Michael, Othus, Megan, Appelbaum, Frederick R.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209396/
https://ncbi.nlm.nih.gov/pubmed/24579885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12778
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items